Skip to search formSkip to main contentSkip to account menu

niraparib

Known as: 2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide 
An inhibitor of poly (ADP-ribose) polymerase (PARP) with potential antineoplastic activity. Niraparib inhibits PARP activity, enhancing the… 
National Institutes of Health

Related topics

Related topics

6 relations

Broader (3)

IndazolesPiperidinesPoly(ADP-ribose) Polymerase Inhibitors

Narrower (1)

MK 4827
NCIt Antineoplastic Agent TerminologyPARP1 protein, human

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
PARP inhibition synergizes with melphalan but does not reverse resistance completely.
2019
2019
Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer: A randomized controlled chemotherapy-free study—NSGO-AVANOVA2/ENGOT-OV24.
5505 Background: Standard treatment of platinum-sensitive recurrent ovarian cancer (PSROC) is platinum based combination… 
2019
2019
Abstract PD5-02: Durability of clinical benefit with niraparib + pembrolizumab in patients with advanced triple-negative breast cancer beyondBRCA: (TOPACIO/Keynote-162)
Background: PARP inhibitor (PARPi) monotherapy has previously demonstrated clinical activity only in patients with a germline… 
2019
2019
A randomized phase II trial of niraparib plus either nivolumab or ipilimumab in patients with advanced pancreatic cancer whose cancer has not progressed on platinum-based therapy.
TPS4161 Background: The treatment paradigm for advanced pancreatic ductal adenocarcinoma (PDAC) typically involves ongoing… 
Review
2018
Review
2018
The promising PARP inhibitors in ovarian cancer therapy: From Olaparib to others.
  • Ying ChenHui Du
  • Biomedicine & pharmacotherapy = Biomedecine…
  • 2018
  • Corpus ID: 48356688
2018
2018
Acquired resistance of phosphatase and tensin homolog‐deficient cells to poly(ADP‐ribose) polymerase inhibitor and Ara‐C mediated by 53BP1 loss and SAMHD1 overexpression
With increasing uses of poly(ADP‐ribose) polymerase (PARP) inhibitors (PARPi) for cancer therapy, understanding their resistance… 
2017
2017
Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: Results from the ENGOT-OV16/NOVA trial
A.M. Oza, U.A. Matulonis, S. Malander, J. Sehouli, J.M. del Campo, D. BerthonRigaud, S. Banerjee, G. Scambia, J.S. Berek, B. Lund… 
2017
2017
Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy.
5517Background: Therapeutic paradigms for recurrent OC vary by geography. Maintenance following response to platinum-based… 
2016
2016
A phase I study of bevacizumab in combination with niraparib in patients with platinum-sensitive epithelial ovarian cancer: The ENGOT-OV24/AVANOVA1 trial.
5555Background: PARP-inhibitors and anti-angiogenic agents are active substances against ovarian cancer (OC). We investigated the… 
2016
2016
Phase I/II study of niraparib plus pembrolizumab in patients with triple-negative breast cancer or recurrent ovarian cancer (KEYNOTE-162).
TPS5599Background: Homologous recombination defects are common in triple-negative breast cancer and high-grade serous ovarian… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)